Guha A, Dey AK, Arora S, et al. - Given a significant reduction in the primary endpoint of death, stroke, and rehospitalizations among patients with severe, symptomatic aortic stenosis who were at low surgical risk, researchers here investigated if patients with cancer and severe aortic stenosis, who are often considered ineligible for surgical aortic valve replacement (SAVR), have shared the same benefits of transcatheter aortic valve replacement (TAVR). The US-based National Inpatient Sample was queried between 2012 and 2015 yielded data from 47,295 TAVRs (22.6% comorbid cancer) and 113,405 SAVRs (15.2% comorbid cancer) performed among admissions with aortic stenosis. The analysis suggest a steady increase in the use of TAVR in patients with cancer compared with patients without cancer. Patients with cancer exhibited a correlation of TAVR with a lower risk of acute kidney injury, lower length of stay, and a higher likelihood of discharge to home when compared with patients undergoing surgical aortic valve replacement. Findings thereby imply that transcatheter therapies have increased access to aortic valve replacement in a population at high risk for surgery and offered an added option for patients who may not have been earlier eligible for therapy.